Compare BridgeBio Pharma Inc (BBIO) vs YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF (QDTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF — how do they compare? BridgeBio Pharma Inc trades at $84.12 (market cap $16.46B), while YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF trades at $41.16. The key difference: BridgeBio Pharma Inc is trading nearer its 52-week high, YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF nearer its low. Which is the better fit depends on your goals.
| BBIO | QDTY | |
|---|---|---|
Market Cap | $16.46B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $90.17 | $46.71 |
52-Week Low | $44.81 | $36.57 |
Enterprise Value | $18.02B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
QDTY trades at $40.43, down 1.84% today amid bearish technical signals. The stock faces selling pressure with moving averages indicating a downtrend, while oscillators remain neutral. Recent weekly dividend announcements from YieldMax ETFs highlight the fund's distribution strategy, though key financial ratios are currently unavailable for fundamental assessment.
The outlook remains cautious with technical indicators pointing to continued weakness. Investment opportunity hinges on the ETF's ability to maintain consistent distributions, while risks include market volatility and the absence of clear valuation metrics. Investors should await updated financial disclosures for fundamental clarity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF
QDTY is an actively managed ETF that employs a synthetic covered call strategy on the Nasdaq-100 Index using zero-days-to-expiration (0DTE) options. It aims to generate high weekly income by selling daily call options, providing limited participation in the index's upside while remaining fully exposed to its downside risk.
Read more on QDTY →
